mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2024-6-7-13mrj-1661Research ArticleЛЕКЦИЯLECTUREЦитомегаловирусная инфекция и иммуновоспалительные ревматические заболевания: что известно сегодняCytomegalovirus infection and immune-mediated inflammatory rheumatic diseases: what is known todayhttps://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

Борис Сергеевич Белов

115522, Москва, Каширское шоссе, 34А

Boris Sergeevich Belov

34A, Kashirskoe Shosse, Moscow 115522

belovbor@yandex.ruhttps://orcid.org/0000-0003-4327-6720МуравьеваН. В.MuravyovaN. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202413122024186713Copyright © Белов Б.С., Муравьева Н.В., 20242024Белов Б.С., Муравьева Н.В.Belov B.S., Muravyova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1661

Цитомегаловирусная инфекция (ЦМВИ) – широко распространенная вирусная антропонозная инфекция, характеризующаяся многообразными клиническими и лабораторными признаками. Появляется все больше данных о связи цитомегаловируса с развитием иммуновоспалительных ревматических заболеваний (ИВРЗ). Наличие иммунопатологических нарушений, вызванных как самим заболеванием, так и применением препаратов с иммуносупресивным действием, обусловливает достаточно высокую распространенность коморбидной активной ЦМВИ у больных с ИВРЗ. Общность клинической картины ЦМВИ и отдельных ИВРЗ нередко создает проблемы при диагностике и разграничении этих заболеваний. Отсутствие рекомендаций по рациональному применению противовирусных препаратов с лечебной и профилактической целью при ИВРЗ диктует необходимость проведения дальнейших исследований.

Cytomegalovirus (CMV) infection is a common viral anthroponotic infection characterized by a variety of clinical and laboratory symptoms. There is a growing body of data on the association between CMV and the development of immune-mediated inflammatory rheumatic diseases (IIRD). The presence of immunopathological disorders caused both by the disease itself and using drugs with immunosuppressive effect determines the relatively high prevalence of comorbid active CMV in patients with IIRD. The commonality of the clinical picture of CMV infection and individual IIRDs often leads to problems in the diagnosis and differentiation between these diseases. The lack of recommendations for the rational use of antiviral drugs for therapeutic and prophylactic purposes in IIRD calls for further research.

цитомегаловирусная инфекцияиммуновоспалительные ревматические заболеваниямолекулярная мимикрияактивация в присутствии свидетелякоморбидностьлечениепрофилактикаcytomegalovirus infectionimmune-inflammatory rheumatic diseasesmolecular mimicrybystander activationcomorbiditytreatmentpreventionСтатья подготовлена в рамках научно-исследовательской работы, № государственного задания 1021051503137-7.The article was created as part of the research work, state assignment №1021051503137-7.ReferencesЦитомегаловирусная болезнь у взрослых. Клинические рекомендации. https://medi.ru/klinicheskie-rekomendatsii/tsitomegalovirusnayabolezn-u-vzroslykh_14305/Cytomegalovirus disease in adults. Clinical recommendations. https://medi.ru/klinicheskie-rekomendatsii/tsitomegalovirusnayabolezn-u-vzroslykh_14305/Muryoi T, Kasturi KN, Kafina MJ, et al. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J Exp Med. 1992 Apr 1;175(4):1103-9. doi: 10.1084/jem.175.4.1103.Muryoi T, Kasturi KN, Kafina MJ, et al. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J Exp Med. 1992 Apr 1;175(4):1103-9. doi: 10.1084/jem.175.4.1103.Lunardi C, Bason C, Navone R, et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med. 2000 Oct;6(10): 1183-6. doi: 10.1038/80533.Lunardi C, Bason C, Navone R, et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med. 2000 Oct;6(10): 1183-6. doi: 10.1038/80533.HoHsieh A, Wang CM, Wu YJ, et al. B cell epitope of human cytomegalovirus phosphoprotein 65 (HCMV pp65) induced anti-dsDNA antibody in BALB/c mice. Arthritis Res Ther. 2017 Mar 21;19(1):65. doi: 10.1186/s13075-017-1268-2.HoHsieh A, Wang CM, Wu YJ, et al. B cell epitope of human cytomegalovirus phosphoprotein 65 (HCMV pp65) induced anti-dsDNA antibody in BALB/c mice. Arthritis Res Ther. 2017 Mar 21;19(1):65. doi: 10.1186/s13075-017-1268-2.Liu Y, Mu R, Gao YP, et al. A Cytomegalovirus Peptide-Specific Antibody Alters Natural Killer Cell Homeostasis and Is Shared in Several Autoimmune Diseases. Cell Host Microbe. 2016 Mar 9;19(3):400-8. doi: 10.1016/j.chom.2016.02.005.Liu Y, Mu R, Gao YP, et al. A Cytomegalovirus Peptide-Specific Antibody Alters Natural Killer Cell Homeostasis and Is Shared in Several Autoimmune Diseases. Cell Host Microbe. 2016 Mar 9;19(3):400-8. doi: 10.1016/j.chom.2016.02.005.Hsieh AH, Jhou YJ, Liang CT, et al. Fragment of tegument protein pp65 of human cytomegalovirus induces autoantibodies in BALB/c mice. Arthritis Res Ther. 2011;13(5): R162. doi: 10.1186/ar3481. Epub 2011 Oct 11.Hsieh AH, Jhou YJ, Liang CT, et al. Fragment of tegument protein pp65 of human cytomegalovirus induces autoantibodies in BALB/c mice. Arthritis Res Ther. 2011;13(5): R162. doi: 10.1186/ar3481. Epub 2011 Oct 11.Neo JYJ, Wee SYK, Bonne I, et al. Characterisation of a human antibody that potentially links cytomegalovirus infection with systemic lupus erythematosus. Sci Rep. 2019 Jul 10;9(1): 9998. doi: 10.1038/s41598-019-46329-y.Neo JYJ, Wee SYK, Bonne I, et al. Characterisation of a human antibody that potentially links cytomegalovirus infection with systemic lupus erythematosus. Sci Rep. 2019 Jul 10;9(1): 9998. doi: 10.1038/s41598-019-46329-y.Varani S, Cederarv M, Feld S, et al. Human cytomegalovirus differentially controls B cell and T cell responses through effects on plasmacytoid dendritic cells. J Immunol. 2007 Dec 1;179(11):7767-76. doi: 10.4049/jimmunol.179.11.7767.Varani S, Cederarv M, Feld S, et al. Human cytomegalovirus differentially controls B cell and T cell responses through effects on plasmacytoid dendritic cells. J Immunol. 2007 Dec 1;179(11):7767-76. doi: 10.4049/jimmunol.179.11.7767.Xu H, Dong P, Ma X, et al B cell-activating factor regulates the survival of B lymphocytes infected with human cytomegalovirus. Immunol Lett. 2017 Jul:187:1-6. doi: 10.1016/j.imlet.2017.04.013. Epub 2017 Apr 23.Xu H, Dong P, Ma X, et al B cell-activating factor regulates the survival of B lymphocytes infected with human cytomegalovirus. Immunol Lett. 2017 Jul:187:1-6. doi: 10.1016/j.imlet.2017.04.013. Epub 2017 Apr 23.Bano A, Pera A, Almoukayed A, et al. CD28 null CD4 T-cell expansions in autoimmune disease suggest a link with cytomegalovirus infection. F1000Res. 2019 Mar 25;8: F1000 Faculty Rev-327. doi: 10.12688/f1000research.17119.1Bano A, Pera A, Almoukayed A, et al. CD28 null CD4 T-cell expansions in autoimmune disease suggest a link with cytomegalovirus infection. F1000Res. 2019 Mar 25;8: F1000 Faculty Rev-327. doi: 10.12688/f1000research.17119.1Wu CS, Chyuan IT, Chiu YL, et al Preserved specific anti-viral T-cell response but associated with decreased lupus activity in SLE patients with cytomegalovirus infection. Rheumatology (Oxford). 2020 Nov 1;59(11): 3340-3349. doi: 10.1093/rheumatology/keaa143.Wu CS, Chyuan IT, Chiu YL, et al Preserved specific anti-viral T-cell response but associated with decreased lupus activity in SLE patients with cytomegalovirus infection. Rheumatology (Oxford). 2020 Nov 1;59(11): 3340-3349. doi: 10.1093/rheumatology/keaa143.Zabalza A, Vera A, Alari-Pahissa E, et al. Impact of cytomegalovirus infection on B cell differentiation and cytokine production in multiple sclerosis. J Neuroinflammation. 2020 May 20;17(1):161. doi: 10.1186/s12974-020-01840-2.Zabalza A, Vera A, Alari-Pahissa E, et al. Impact of cytomegalovirus infection on B cell differentiation and cytokine production in multiple sclerosis. J Neuroinflammation. 2020 May 20;17(1):161. doi: 10.1186/s12974-020-01840-2.Li TH, Su CF, Lai CC, et al. Epidemiology and risk factors for cytomegalovirus disease in autoimmune inflammatory rheumatic diseases: A nationwide population-based study in Taiwan. Int J Rheum Dis. 2024 Feb;27(2): e15067. doi: 10.1111/1756-185X.15067.Li TH, Su CF, Lai CC, et al. Epidemiology and risk factors for cytomegalovirus disease in autoimmune inflammatory rheumatic diseases: A nationwide population-based study in Taiwan. Int J Rheum Dis. 2024 Feb;27(2): e15067. doi: 10.1111/1756-185X.15067.Ogata H, Aoki N, Nagano K, et al. Factors associated with cytomegalovirus antigenemia in patients with rheumatic disease: A retrospective study. J Infect Chemother. 2022 Nov;28(11):1471-1477. doi: 10.1016/j.jiac.2022.07.004. Epub 2022 Jul 16.Ogata H, Aoki N, Nagano K, et al. Factors associated with cytomegalovirus antigenemia in patients with rheumatic disease: A retrospective study. J Infect Chemother. 2022 Nov;28(11):1471-1477. doi: 10.1016/j.jiac.2022.07.004. Epub 2022 Jul 16.Suga K, Nishiwaki A, Nakamura T, Kagami SI. Clinical significance of cytomegalovirus (CMV) pp65 antigenemia in the prediction of CMV infection during immunosuppressive therapy for rheumatic disease. Rheumatol Int. 2023 Jun;43(6):1093-1099. doi: 10.1007/s00296-022-05196-z. Epub 2022 Aug 30.Suga K, Nishiwaki A, Nakamura T, Kagami SI. Clinical significance of cytomegalovirus (CMV) pp65 antigenemia in the prediction of CMV infection during immunosuppressive therapy for rheumatic disease. Rheumatol Int. 2023 Jun;43(6):1093-1099. doi: 10.1007/s00296-022-05196-z. Epub 2022 Aug 30.Kaneshita S, Kida T, Yokota I, et al. Risk factors for cytomegalovirus disease with cytomegalovirus re-activation in patients with rheumatic disease. Mod Rheumatol. 2020 Jan; 30(1):109-115. doi: 10.1080/14397595.2018.1551264. Epub 2019 Jan 3.Kaneshita S, Kida T, Yokota I, et al. Risk factors for cytomegalovirus disease with cytomegalovirus re-activation in patients with rheumatic disease. Mod Rheumatol. 2020 Jan; 30(1):109-115. doi: 10.1080/14397595.2018.1551264. Epub 2019 Jan 3.Shimada T, Higashida-Konishi M, Izumi K, et al. Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study. Sci Rep. 2022 Dec 3;12(1):20926. doi: 10.1038/s41598-022-25451-4.Shimada T, Higashida-Konishi M, Izumi K, et al. Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study. Sci Rep. 2022 Dec 3;12(1):20926. doi: 10.1038/s41598-022-25451-4.Tani C, Carli L, Mosca M, et al. Occurrence and risk factors for cytomegalovirus infection in hospitalized systemic lupus erythematosus patients. Ann Rheum Dis. 2010; 69 (Suppl 3):572.Tani C, Carli L, Mosca M, et al. Occurrence and risk factors for cytomegalovirus infection in hospitalized systemic lupus erythematosus patients. Ann Rheum Dis. 2010; 69 (Suppl 3):572.Choo HMC, Cher WQ, Kwan YH, Fong WWS. Risk factors for cytomegalovirus disease in systemic lupus erythematosus (SLE): a systematic review. Adv Rheumatol. 2019 Mar 18;59(1):12. doi: 10.1186/s42358-019-0055-y.Choo HMC, Cher WQ, Kwan YH, Fong WWS. Risk factors for cytomegalovirus disease in systemic lupus erythematosus (SLE): a systematic review. Adv Rheumatol. 2019 Mar 18;59(1):12. doi: 10.1186/s42358-019-0055-y.Jia J, Shi H, Liu M, et al. Cytomegalovirus Infection May Trigger Adult-Onset Still's Disease Onset or Relapses. Front Immunol. 2019 Apr 24:10:898. doi: 10.3389/fimu.2019.00898. eCollection 2019.Jia J, Shi H, Liu M, et al. Cytomegalovirus Infection May Trigger Adult-Onset Still's Disease Onset or Relapses. Front Immunol. 2019 Apr 24:10:898. doi: 10.3389/fimu.2019.00898. eCollection 2019.Kronbichler A, Leierer J, Leierer G, et al. Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibodyassociated vasculitides. Rheumatology (Oxford). 2017 May 1;56(5):704-708. doi: 10.1093/rheumatology/kew465.Kronbichler A, Leierer J, Leierer G, et al. Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibodyassociated vasculitides. Rheumatology (Oxford). 2017 May 1;56(5):704-708. doi: 10.1093/rheumatology/kew465.Henry N, Brilland B, Wacrenier S, et al Incidence and Risk Factors of Venous Thromboembolic Events in Patients with ANCA-Glomerulonephritis: A Cohort Study from the Maine-Anjou Registry. J Clin Med. 2020 Sep 30;9(10):3177. doi: 10.3390/jcm9103177.Henry N, Brilland B, Wacrenier S, et al Incidence and Risk Factors of Venous Thromboembolic Events in Patients with ANCA-Glomerulonephritis: A Cohort Study from the Maine-Anjou Registry. J Clin Med. 2020 Sep 30;9(10):3177. doi: 10.3390/jcm9103177.Liapi M, Jayne D, Merkel PA, et al. Venous thromboembolism in ANCA-associated vasculitis: a population-based cohort study. Rheumatology (Oxford). 2021 Oct 2;60(10): 4616-4623. doi: 10.1093/rheumatology/keab057.Liapi M, Jayne D, Merkel PA, et al. Venous thromboembolism in ANCA-associated vasculitis: a population-based cohort study. Rheumatology (Oxford). 2021 Oct 2;60(10): 4616-4623. doi: 10.1093/rheumatology/keab057.King C, Patel R, Mendoza C, et al Cytomegalovirus infection is a risk factor for venous thromboembolism in ANCA-associated vasculitis. Arthritis Res Ther. 2022 Aug 10; 24(1):192. doi: 10.1186/s13075-022-02879-7.King C, Patel R, Mendoza C, et al Cytomegalovirus infection is a risk factor for venous thromboembolism in ANCA-associated vasculitis. Arthritis Res Ther. 2022 Aug 10; 24(1):192. doi: 10.1186/s13075-022-02879-7.Kelkar AH, Jacob KS, Yousif EB, Farrell JJ. Venous thromboembolism related to cytomegalovirus infection: A case report and literature review. Medicine (Baltimore). 2017 Dec;96(51):e9336. doi: 10.1097/MD.0000000000009336.Kelkar AH, Jacob KS, Yousif EB, Farrell JJ. Venous thromboembolism related to cytomegalovirus infection: A case report and literature review. Medicine (Baltimore). 2017 Dec;96(51):e9336. doi: 10.1097/MD.0000000000009336.Wolf G, Porth J, Stahl RA. Thrombosis associated with cytomegalovirus infection in patients with ANCA-positive vasculitis. Am J Kidney Dis. 2001 Nov;38(5):E27. doi: 10.1053/ajkd.2001.29576.Wolf G, Porth J, Stahl RA. Thrombosis associated with cytomegalovirus infection in patients with ANCA-positive vasculitis. Am J Kidney Dis. 2001 Nov;38(5):E27. doi: 10.1053/ajkd.2001.29576.Chanouzas D, Sagmeister M, Faustini S, et al. Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. J Infect Dis. 2019 Jan 7;219(2):234-244. doi: 10.1093/infdis/jiy493.Chanouzas D, Sagmeister M, Faustini S, et al. Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. J Infect Dis. 2019 Jan 7;219(2):234-244. doi: 10.1093/infdis/jiy493.Forte E, Swaminathan S, Schroeder MW, et al. Tumor Necrosis Factor Alpha Induces Reactivation of Human Cytomegalovirus Independently of Myeloid Cell Differentiation following Posttranscriptional Establishment of Latency. mBio. 2018 Sep 11;9(5):e01560-18. doi: 10.1128/mBio.01560-18.Forte E, Swaminathan S, Schroeder MW, et al. Tumor Necrosis Factor Alpha Induces Reactivation of Human Cytomegalovirus Independently of Myeloid Cell Differentiation following Posttranscriptional Establishment of Latency. mBio. 2018 Sep 11;9(5):e01560-18. doi: 10.1128/mBio.01560-18.Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis (REACTIVAS). https://clinicaltrials.gov/study/NCT04916704?cond=%20Anca%20Vasculitides&rank=5.Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis (REACTIVAS). https://clinicaltrials.gov/study/NCT04916704?cond=%20Anca%20Vasculitides&rank=5.Takizawa Y, Inokuma S, Tanaka Y, et al. Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population. Rheumatology (Oxford). 2008 Sep;47(9):1373-8. doi: 10.1093/rheumatology/ken231. Epub 2008 Jun 24.Takizawa Y, Inokuma S, Tanaka Y, et al. Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population. Rheumatology (Oxford). 2008 Sep;47(9):1373-8. doi: 10.1093/rheumatology/ken231. Epub 2008 Jun 24.Егорова ОН, Балабанова РМ, Сажина ЕГ. Системная красная волчанка и оппортунистические инфекции: распространенность, клинические особенности. Современная ревматология. 2008;2(4):27-33. doi: 10.14412/1996-7012-2008-503Egorova ON, Balabanova RM, Sazhina EG. Systemic lupus erythematosus and opportunistic infections: prevalence, clinical features. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2008;2(4):27-33. (In Russ.) doi: 10.14412/1996-7012-2008-503Chen Y, Zhong J, Liu X, et al. Cytomegalovirus antigen-specific multi-cytokine immune responses in patients with rheumatic diseases under different cytomegalovirus infection status: A case-control study. Clin Chim Acta. 2024 Jul 15:561:119828. doi: 10.1016/j.cca.2024.119828. Epub 2024 Jun 22.Chen Y, Zhong J, Liu X, et al. Cytomegalovirus antigen-specific multi-cytokine immune responses in patients with rheumatic diseases under different cytomegalovirus infection status: A case-control study. Clin Chim Acta. 2024 Jul 15:561:119828. doi: 10.1016/j.cca.2024.119828. Epub 2024 Jun 22.Mingli H, Tsai CY. Analysis of clinical features and risk factors of in-hospital mortality in cytomegalovirus (CMV) diseases with systemic lupus erythematosus. Ann Rheum Dis. 2018:77(Suppl.):A1441.Mingli H, Tsai CY. Analysis of clinical features and risk factors of in-hospital mortality in cytomegalovirus (CMV) diseases with systemic lupus erythematosus. Ann Rheum Dis. 2018:77(Suppl.):A1441.Zhang T, Yu Z, Gao S, et al. Clinical phenotypes and prognosis of cytomegalovirus infection in the pediatric systemic lupus erythematosus: a longitudinal analysis. Pediatr Rheumatol Online J. 2023 Mar 16;21(1):25. doi: 10.1186/s12969-023-00807-w.Zhang T, Yu Z, Gao S, et al. Clinical phenotypes and prognosis of cytomegalovirus infection in the pediatric systemic lupus erythematosus: a longitudinal analysis. Pediatr Rheumatol Online J. 2023 Mar 16;21(1):25. doi: 10.1186/s12969-023-00807-w.Sebastiani GD, Iuliano A, Canofari C, Bracci M. Cytomegalovirus infection in Systemic Lupus Erythematosus: report of four cases challenging the management of the disease, and literature review. Lupus. 2019 Mar; 28(3):432-437. doi: 10.1177/0961203319825570. Epub 2019 Jan 24.Sebastiani GD, Iuliano A, Canofari C, Bracci M. Cytomegalovirus infection in Systemic Lupus Erythematosus: report of four cases challenging the management of the disease, and literature review. Lupus. 2019 Mar; 28(3):432-437. doi: 10.1177/0961203319825570. Epub 2019 Jan 24.Lim CC, Tan BH, Tung YT, et al. Riskstratified approach to anti-viral prophylaxis against cytomegalovirus disease in glomerulonephritis and renal vasculitis treated with potent immunosuppressants. Infect Dis (Lond). 2019 Oct;51(10):745-752. doi: 10.1080/23744235.2019.1648855. Epub 2019 Aug 13.Lim CC, Tan BH, Tung YT, et al. Riskstratified approach to anti-viral prophylaxis against cytomegalovirus disease in glomerulonephritis and renal vasculitis treated with potent immunosuppressants. Infect Dis (Lond). 2019 Oct;51(10):745-752. doi: 10.1080/23744235.2019.1648855. Epub 2019 Aug 13.Liu P, Tan HZ, Li H, et al. Infections in hospitalized lupus nephritis patients: characteristics, risk factors, and outcomes. Lupus. 2018 Jun;27(7):1150-1158. doi: 10.1177/0961203318768881. Epub 2018 Apr 9.Liu P, Tan HZ, Li H, et al. Infections in hospitalized lupus nephritis patients: characteristics, risk factors, and outcomes. Lupus. 2018 Jun;27(7):1150-1158. doi: 10.1177/0961203318768881. Epub 2018 Apr 9.

The authors declare that there are no conflicts of interest present.